Premium
A new, bioactive, antibacterial‐eluting, composite graft for infection‐free wound healing
Author(s) -
Mittal Anupama,
Kumar Neeraj
Publication year - 2014
Publication title -
wound repair and regeneration
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.847
H-Index - 109
eISSN - 1524-475X
pISSN - 1067-1927
DOI - 10.1111/wrr.12194
Subject(s) - gentamicin , wound healing , antibiotics , in vivo , histology , fibroblast , breaking strength , reticular connective tissue , colony forming unit , chemistry , medicine , surgery , in vitro , pathology , bacteria , biology , materials science , biochemistry , genetics , microbiology and biotechnology , composite material
The current work focuses on the in vivo performance of a newly developed injectable composite graft in infected full‐thickness wounds. The composite graft was composed of bioactive porous P oly dl‐lactide‐co‐glycolide scaffolds, antibiotic gentamicin, and crosslinked gelatin as carrier gel. Treated infected wounds exhibited a faster wound closure, rapid weight gain, lower neutrophil count, higher breaking strength, and 100 times lesser microbial count (10 2 colony forming units/g in infected treated vs. 10 4 colony forming units/g in infected control group) in comparison with infected control group 28 days post treatment. During healing, collagen production was more in the treated groups at day 7 than controls and thereafter gradually reduced to normal levels. Histology revealed a mature scar tissue formation, fibroblast proliferation, epidermal resurfacing, and collagen deposition in reticular alignment similar to normal healthy skin in treated wounds. Further, the plasma concentration of gentamicin was 35–45 μg/mL during the initial 12 hours and reduced to 1 μg/mL in 24 hours, which indicated safe levels of the antibiotic drug during healing. These results clearly indicate a faster, infection‐free, and safe after treatment with the developed graft.